Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival

References

• Yano H, Moran BJ, Cecil TD, Murphy EM. (2009). Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol 35:980–5.
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Cabras AD, et al. (2013). Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 49:3140–8.
   PubMed Web of Science ®Google Scholar
• Mohamed F, Sugarbaker PH. (2002). Peritoneal mesothelioma. Curr Treat Options Oncol 3:375–86.
   PubMedGoogle Scholar
• Mohamed F, Cecil T, Moran B, Sugarbaker P. (2011). A new standard of care for the management of peritoneal surface malignancy. Curr Oncol 18:e84–96.
   PubMed Web of Science ®Google Scholar
• Garcia-Fadrique A, Mehta A, Mohamed F, et al. (2017). Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. J Gastrointest Oncol 8:915–24.
   PubMed Web of Science ®Google Scholar
• Maurer R, Egloff B. (1975). Malignant peritoneal mesothelioma after cholangiography with thorotrast. Cancer 36:1381–5.
   PubMed Web of Science ®Google Scholar
• Testa JR, Carbone M, Hirvonen A, et al. (1998). A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res 58:4505–9.
   PubMed Web of Science ®Google Scholar
• Baumann F, Ambrosi JP, Carbone M. (2013). Asbestos is not just asbestos: an unrecognised health hazard. Lancet Oncol 14:576–8.
   PubMed Web of Science ®Google Scholar
• Liu S, Staats P, Lee M, et al. (2014). Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients. Pathology 46:604–9.
   PubMed Web of Science ®Google Scholar
• Cleaver AL, Bhamidipaty K, Wylie B, et al. (2014). Long-term exposure of mesothelial cells to SV40 and asbestos leads to malignant transformation and chemotherapy resistance. Carcinogenesis 35:407–14.
   PubMed Web of Science ®Google Scholar
• Dogan AU, Baris YI, Dogan M, et al. (2006). Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 66:5063–8.
   PubMed Web of Science ®Google Scholar
• Chua TC, Yan TD, Deraco M, et al. (2011). Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. Br J Surg 98:60–4.
   PubMed Web of Science ®Google Scholar
• Mohamed F, Sethna K, Elias D, Sugarbaker PH. (2003). Challenging and unusual cases: Case 3. Peritoneal cystic mesothelioma. J Clin Oncol 21:1419–20.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–44.
   PubMed Web of Science ®Google Scholar
• Simon GR, Verschraegen CF, Janne PA, et al. (2008). Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 26:3567–72.
   PubMed Web of Science ®Google Scholar
• Yan TD, Deraco M, Baratti D, et al. (2009). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–42.
   PubMed Web of Science ®Google Scholar
• Hompes D, D'Hoore A, Van Cutsem E, et al. (2012). The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Ann Surg Oncol 19:2186–94.
   PubMed Web of Science ®Google Scholar
• Bretcha-Boix P, Farre-Alegre J, Sureda M, et al. (2010). Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years' experience of a new centre for peritoneal surface malignancies. Clin Transl Oncol 12:437–42.
   PubMed Web of Science ®Google Scholar
• Malpica A, Sant'Ambrogio S, Deavers MT, Silva EG. (2012). Well-differentiated papillary mesothelioma of the female peritoneum. A clinicopathologic study of 26 cases. Am J Surg Pathol 36:117–27.
   PubMed Web of Science ®Google Scholar
• Chen X, Sheng W, Wang J. (2013). Well-differentiated papillary mesothelioma: a clinicopathological and immunohistochemical study of 18 cases with additional observation. Histopathology 62:805–13.
   PubMed Web of Science ®Google Scholar
• Sethna K, Mohamed F, Marchettini P, et al. (2003). Peritoneal cystic mesothelioma: a case series. Tumori 89:31–5.
   PubMed Web of Science ®Google Scholar
• Attanoos RL, Gibbs AR. (1997). Pathology of malignant mesothelioma. Histopathology 30:403–18.
   PubMed Web of Science ®Google Scholar
• Cerruto CA, Brun EA, Chang D, Sugarbaker PH. (2006). Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med 130:1654–61.
   PubMed Web of Science ®Google Scholar
• Viale G, Giobbie-Hurder A, Regan MM, et al. (2008). Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569–75.
   PubMed Web of Science ®Google Scholar
• Burkhart RA, Ronnekleiv-Kelly SM, Pawlik TM. (2017). Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response. Surg Oncol 26:138–45.
   PubMed Web of Science ®Google Scholar
• Deraco M, Cabras A, Baratti D, Kusamura S. (2015). Immunohistochemical evaluation of minichromosome maintenance protein 7 (MCM7), topoisomerase IIalpha, and Ki-67 in diffuse malignant peritoneal mesothelioma patients using tissue microarray. Ann Surg Oncol 22:4344–51.
   PubMed Web of Science ®Google Scholar
• Pillai K, Pourgholami MH, Chua TC, Morris DL. (2015). Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma. Am J Clin Oncol 38:388–94.
   PubMed Web of Science ®Google Scholar
• Kusamura S, Torres Mesa PA, Cabras A, et al. (2016). The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 23:1468–73.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Sugarbaker PH. (1996). Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–74.
   PubMedGoogle Scholar
• Facchiano E, Scaringi S, Kianmanesh R, et al. (2008). Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol 34:154–8.
   PubMed Web of Science ®Google Scholar
• Valle M, Van der Speeten K, Garofalo A. (2009). Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients. J Surg Oncol 100:331–4.
   PubMed Web of Science ®Google Scholar
• Dayal S, Taflampas P, Riss S, et al. (2013). Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum 56:1366–72.
   PubMed Web of Science ®Google Scholar
• Alexander-Sefre F, Chandrakumaran K, Banerjee S, et al. (2005). Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence. Colorectal Dis 7:382–6.
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Martinetti A, et al. (2007). Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 14:500–8.
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Deraco M. (2009). Circulating CA125 and diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 35:1198–9.
   PubMed Web of Science ®Google Scholar
• Di Fabio F, Aston W, Mohamed F, et al. (2015). Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei one week after complete tumour removal. Colorectal Dis 17:698–703.
   PubMed Web of Science ®Google Scholar
• Dayal S, Ghosh D, Moran B. (2014). Miscellaneous conditions of the peritoneal cavity–peritoneal tumors, pseudomyxoma, mesothelioma, fibroblastic reaction, cocoon, cystic lymphatic malformations, blue-bleb, and chylous ascites. Semin Pediatr Surg 23:363–8.
   PubMed Web of Science ®Google Scholar
• Antman KH, Pomfret EA, Aisner J, et al. (1983). Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1:386–91.
   PubMed Web of Science ®Google Scholar
• Alexander HR, Jr, Burke AP. (2016). Diagnosis and management of patients with malignant peritoneal mesothelioma. J Gastrointest Oncol 7:79–86.
   PubMed Web of Science ®Google Scholar
• Yan TD, Welch L, Black D, Sugarbaker PH. (2007). A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18:827–34.
   PubMed Web of Science ®Google Scholar
• Moran B, Cecil T, Chandrakumaran K, et al. (2015). The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis 17:772–8.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Yan TD, Stuart OA, Yoo D. (2006). Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 32:686–91.
   PubMed Web of Science ®Google Scholar
• Kluger MD, Taub RN, Hesdorffer M, et al. (2010). Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials. Eur J Surg Oncol 36:997–1003.
   PubMed Web of Science ®Google Scholar
• Wong RM, Ianculescu I, Sharma S, et al. (2014). Immunotherapy for malignant pleural mesothelioma. Current status and future prospects. Am J Respir Cell Mol Biol 50:870–5.
   PubMed Web of Science ®Google Scholar
• Calabro L, Maio M. (2015). Immune checkpoint blockade in malignant mesothelioma. Semin Oncol 42:418–22.
   PubMed Web of Science ®Google Scholar